Multi-arm international trial evaluates investigational therapies to slow or halt Parkinson's disease progression in prodromal patients Zeist, the Netherlands, and Atlanta, GA — July 7, 2026 — P95 Julius Clinical, a global, science-led cont...
The GRIPonMASH consortium has reached a significant milestone in screening individuals at risk of metabolic dysfunction-associated steatotic liver disease (MASLD). Julius Clinical is proud to contribute to this achievement. The GRIPonMASH conso...
500+ person global organization spans 25+ countries with operations across North America, Europe, Africa, Latin America, and Asia-Pacific
Zeist, The Netherlands – September 23, 2025 – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic diseases, is pleased to announce the appointment of Bassem Saleh ...
Zeist, Netherlands, May 14, 2025– Julius Clinical, a leading full-service Contract Research Organization (CRO) headquartered in the Netherlands (Zeist), and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States (Georg...
Julius Clinical are proud to announce the successful completion of recruitment for the PRImus-AD study, a clinical Phase II study which investigates the safety and efficacy of the drug candidate PRI-002 for the treatment of Alzheimer's Disease. ...
Zeist, Netherlands, [February 25, 2025] – Julius Clinical, a science-driven global CRO specializing in Neurological, Cardio-Metabolic, Renal and Rare Diseases, is pleased to announce the establishment of Julius Clinical Poland, a new operational...
Julius Clinical is proud to announce our continued sponsorship of Bio-Neuroscience 2025, the premier summit for CEOs, investors, and industry decision-makers in CNS neuroscience drug development. Taking place in Amsterdam from 25-27 February 20...
At Julius Clinical, we are proud to announce the first formal meeting of our Dementia Scientific Advisory Board (SAB) with Prof. Philip Scheltens and Prof. John Harrison—a major milestone in our commitment to advancing dementia research and clin...
From being a largely unknown pathogen, Respiratory Syncytial Virus (RSV) is now almost a household word – and a fearful one for families with infants and young children at risk. But new solutions, such as long-acting monoclonal antibodies (mAbs)...
"*" indicates required fields
"*" indicates required fields
